Fate Therapeutics Inc (FRA:F6T)
€ 3.421 -0.17 (-4.73%) Market Cap: 416.24 Mil Enterprise Value: 219.30 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 62/100

Fate Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 09:00PM GMT
Release Date Price: €5 (+10.82%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Perfect. Well, thank you, everyone, for joining us. I'm pleased to be joined by Scott Wolchko, President and CEO of Fate Therapeutics. Thank you so much.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director

Thank you. Thank you for having me.

Questions & Answers

Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Yes, of course. 2023, a lot of changes for Fate, maybe we can start there, just talk us through what happened here? How much change has really come about for Fate on the back of this Janssen termination?

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director

Sure. Obviously, the termination was sudden with respect to its developments. And it really caused us to obviously take a hard look at the strategic direction of the company, our assets, and we continued to favor the development and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot